Global Antacids Market Overview 2023-2028
The global antacids market size reached US$ 6.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4% during 2023-2028.
Over-the-counter antacids are frequently employed to swiftly alleviate heartburn and indigestion. Their mechanism of action involves counterbalancing excessive stomach acid, the primary source of discomfort in these situations. Typically, antacids incorporate alkaline substances like calcium carbonate, magnesium hydroxide, or aluminum hydroxide. By neutralizing the acid, they alleviate the burning sensation and pain linked to heartburn. These remedies offer rapid but temporary relief, rendering them well-suited for sporadic or mild instances of heartburn. They come in various forms, including tablets, chewable tablets, liquids, and effervescent powders, making them easily accessible.
Global Antacids Market Trends and Drivers:
The escalating incidence of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis stands out as a primary catalyst for the global demand for antacids. This trend can also be attributed to shifting lifestyles marked by irregular dietary patterns, disrupted sleep routines, and sedentary living. Furthermore, the wide accessibility of antacids in pharmacies, supermarkets, and online platforms is propelling market expansion. Additionally, the proliferation of advertising and marketing initiatives by pharmaceutical companies promoting antacids as a swift and effective remedy is a driving force behind market growth. Beyond this, the increasing awareness regarding the advantages of antacids is further fortifying market expansion.
Global Antacids Market 2023-2028 Analysis and Segmentation:
Top Key Players covered in this report are: Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited.
The report segmented the market on the basis of region, drug class, formulation type and distribution channel.
Breakup by Drug Class:
- Proton Pump Inhibitors
- H2 Antagonist
- Acid Neutralizers
- Pro-Motility Agents
Breakup by Formulation Type:
- Tablet
- Liquid
- Powder
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Key highlights of the report:
- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800